{"@context":{"@vocab":"https://schema.org/"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/fda/warning-letters/recent","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://creativecommons.org/publicdomain/zero/1.0/","primary_source":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters","generated_at":"2026-10-04T16:29:20.772Z"},"count":6,"filters":{"office":"Division of Biological Products Operations I"},"items":[{"id":"9b5f28861202758d","posted_date":"2024-07-09","letter_issue_date":"2024-06-20","company_name":"New Mexico Lions Sight Conservation Foundation, Inc. dba New Mexico Lions Eye Bank","issuing_office":"Division of Biological Products Operations II","subject":"Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)","canonical_url":"https://api.morvs.ai/fda-warning/9b5f28861202758d"},{"id":"dde3d86b99d3a57f","posted_date":"2024-05-28","letter_issue_date":"2024-04-05","company_name":"Safari Stem Cell, LLC","issuing_office":"Division of Biological Products Operations II","subject":"CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug","canonical_url":"https://api.morvs.ai/fda-warning/dde3d86b99d3a57f"},{"id":"ccd965b7a374e5f7","posted_date":"2024-05-14","letter_issue_date":"2024-04-30","company_name":"Washington Fertility Center","issuing_office":"Division of Biological Products Operations I","subject":"Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)","canonical_url":"https://api.morvs.ai/fda-warning/ccd965b7a374e5f7"},{"id":"773f564a635910d0","posted_date":"2024-01-04","letter_issue_date":"2023-09-01","company_name":"Kimera Labs, Inc.","issuing_office":"Division of Biological Products Operations I","subject":"Investigational Device Exemptions (IDE)","canonical_url":"https://api.morvs.ai/fda-warning/773f564a635910d0"},{"id":"ea154cd6067dcde8","posted_date":"2023-08-01","letter_issue_date":"2023-06-01","company_name":"RenatiLabs Inc.","issuing_office":"Division of Biological Products Operations I","subject":"Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)","canonical_url":"https://api.morvs.ai/fda-warning/ea154cd6067dcde8"},{"id":"1b401b482e4a9126","posted_date":"2023-07-25","letter_issue_date":"2023-06-05","company_name":"Stratus Biosystems, LLC dba CellGenuity Regenerative Science","issuing_office":"Division of Biological Products Operations II","subject":"Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps)","canonical_url":"https://api.morvs.ai/fda-warning/1b401b482e4a9126"}]}